Virax Biolabs Group (VRAX) Competitors $0.88 -0.08 (-8.07%) Closing price 06/13/2025 03:48 PM EasternExtended Trading$0.97 +0.09 (+9.92%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. ATHA, LIPO, BCTX, NERV, BTAI, EQ, AIMD, TRIB, EYEN, and BCDAShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Athira Pharma (ATHA), Lipella Pharmaceuticals (LIPO), BriaCell Therapeutics (BCTX), Minerva Neurosciences (NERV), BioXcel Therapeutics (BTAI), Equillium (EQ), Ainos (AIMD), Trinity Biotech (TRIB), Eyenovia (EYEN), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Athira Pharma Lipella Pharmaceuticals BriaCell Therapeutics Minerva Neurosciences BioXcel Therapeutics Equillium Ainos Trinity Biotech Eyenovia BioCardia Athira Pharma (NASDAQ:ATHA) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Do insiders & institutionals believe in ATHA or VRAX? 57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 22.1% of Athira Pharma shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer ATHA or VRAX? Athira Pharma currently has a consensus price target of $13.83, indicating a potential upside of 4,450.44%. Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 239.94%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ATHA or VRAX? Athira Pharma received 19 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. However, 100.00% of users gave Virax Biolabs Group an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote. CompanyUnderperformOutperformAthira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Virax Biolabs GroupOutperform Votes1100.00% Underperform VotesNo Votes Does the media refer more to ATHA or VRAX? In the previous week, Virax Biolabs Group had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Virax Biolabs Group and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Virax Biolabs Group's score of 1.44 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Very Positive Virax Biolabs Group Positive Is ATHA or VRAX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -115.62% -88.94% Virax Biolabs Group N/A N/A N/A Which has more risk & volatility, ATHA or VRAX? Athira Pharma has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Which has preferable valuation & earnings, ATHA or VRAX? Virax Biolabs Group has higher revenue and earnings than Athira Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$117.67M-$2.07-0.15Virax Biolabs Group$84.87K33.62-$6.73MN/AN/A SummaryVirax Biolabs Group beats Athira Pharma on 9 of the 14 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.85M$2.68B$5.57B$8.50BDividend YieldN/A0.70%5.27%4.17%P/E RatioN/A7.7426.7519.66Price / Sales33.6235.23403.98152.07Price / CashN/A15.7538.2534.64Price / Book0.445.416.964.59Net Income-$6.73M-$65.73M$3.23B$248.23M7 Day Performance-9.81%-4.49%-1.22%-1.07%1 Month Performance-16.75%-0.96%6.34%2.59%1 Year Performance-51.24%-20.94%33.05%13.50% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.3413 of 5 stars$0.88-8.1%$3.00+239.9%-51.2%$2.85M$84.87K0.005Positive NewsShort Interest ↓ATHAAthira Pharma3.0297 of 5 stars$0.34+1.5%$13.83+4,017.1%-88.0%$13.12MN/A-0.1240Gap DownLIPOLipella Pharmaceuticals2.2369 of 5 stars$2.92+0.3%N/A-53.0%$13.04M$536.36K-0.694Positive NewsBCTXBriaCell Therapeutics1.8343 of 5 stars$3.50+0.4%$32.00+815.6%-85.2%$13MN/A-0.268Short Interest ↑NERVMinerva Neurosciences3.3882 of 5 stars$1.85+0.3%$5.00+171.0%-45.5%$12.90MN/A-4.199BTAIBioXcel Therapeutics3.8506 of 5 stars$2.10+6.9%$42.60+1,933.4%-92.9%$12.63M$1.85M-0.0690Short Interest ↑Gap DownEQEquillium2.8401 of 5 stars$0.35-7.4%$3.00+752.3%-51.3%$12.57M$30.41M-2.5140News CoverageGap DownAIMDAinos1.1845 of 5 stars$0.60-2.3%N/A-42.7%$12.55M$106.21K-0.4740Gap DownTRIBTrinity Biotech1.7877 of 5 stars$0.69+5.7%N/A-76.9%$12.49M$61.56M-0.31480Positive NewsAnalyst RevisionEYENEyenovia0.465 of 5 stars$4.16-3.8%$2.00-51.9%-95.2%$11.96M$67.06K-0.0740Short Interest ↑BCDABioCardia3.6916 of 5 stars$2.30+2.7%$25.00+987.0%-36.1%$11.91M$3K-0.5540News CoveragePositive NewsShort Interest ↓ Related Companies and Tools Related Companies Athira Pharma Competitors Lipella Pharmaceuticals Competitors BriaCell Therapeutics Competitors Minerva Neurosciences Competitors BioXcel Therapeutics Competitors Equillium Competitors Ainos Competitors Trinity Biotech Competitors Eyenovia Competitors BioCardia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRAX Stock Free VRAX Stock Alerts